Skip to content

Diagnostic Medicine in Brazil Customer Challenges and Pains Analysis

Challenges and Pains faced by Customers

Based on the analysis of the provided reports, the main challenges and pains faced by customers in the Brazilian Diagnostic Medicine value chain can be categorized based on the customer segments identified in the "Final Customers Identification" report. These challenges stem from various points within the value chain, impacting the accessibility, affordability, quality, and efficiency of diagnostic services.

For Patients (B2C Customers), the primary pains are related to access and affordability. A significant challenge is the disparity in access to diagnostic services between the public healthcare system (SUS) and the supplementary health system, as well as geographical disparities between urban centers and remote areas. This often results in long waiting times for appointments and procedures within the SUS. The affordability of services is another pain point, particularly for those relying on self-pay or facing co-payments, especially for more complex or numerous tests. Patients in underserved areas may also experience limited access to specialized or high-complexity tests. Furthermore, the lack of seamless integration of patient data across different providers and systems can hinder continuity of care and require patients to repeat information or tests.

For B2B Customers, the challenges and pains vary depending on their role:

  • Health Insurance Operators: Their main pain points revolve around the financial aspects of diagnostic services. They face constant pressure on reimbursement rates from diagnostic service providers who seek compensation that reflects their costs and investments. Managing the rising costs of diagnostic services, which accounted for a significant portion of their expenses (21.1% in 2023), is a key challenge. The complexity and bureaucracy of claims submission and authorization processes from providers add administrative burden and can lead to disputes, such as "glosas" (claim denials). Disagreements over the coverage and reimbursement of new or advanced diagnostic technologies are also a challenge.
  • Public Healthcare System (SUS): The SUS faces significant challenges due to funding constraints, impacting its ability to provide timely and comprehensive diagnostic services universally. This contributes to long waiting times and potentially outdated infrastructure in some public facilities. When contracting with private providers to supplement capacity, the low reimbursement rates set by the Tabela SUS are a major pain point for the providers, which can affect the availability and quality of services offered within the public system. Bureaucracy in contracting and payment processes also poses difficulties.
  • Hospitals and Clinics: These entities require timely and accurate diagnostic information for effective patient care and treatment planning. They face challenges in procuring necessary equipment and reagents, which can be affected by import dependency, logistics, and cost pressures throughout the value chain. For those that outsource, contracting with external diagnostic service providers involves negotiating terms and managing these relationships effectively.
  • Companies (for Corporate and Occupational Health): Their primary need is for efficient and reliable diagnostic services for employee health programs.
  • Other Laboratories: Smaller or less specialized laboratories often rely on larger or reference laboratories for specific tests, and their pain point is ensuring access to reliable and timely reference laboratory services.
  • Physicians: As the primary users of diagnostic information, physicians require accurate, timely, and clinically relevant results to guide their medical decisions. A significant pain point is the shortage of specialized professionals like pathologists and radiologists, particularly in certain regions, which can impact the interpretation and reporting of complex tests.

Prioritized table of challenges and pains.

Priority Challenge/Pain Primarily Affects Customer Segment(s)
1 Access Disparities & Long Waiting Times Patients (B2C), Public Healthcare System (SUS - B2B)
2 Pressure on Reimbursement Rates & Payment Delays Health Insurance Operators (B2B), Diagnostic Service Providers (Internal)
3 Cost of Services & Affordability Patients (B2C), Health Insurance Operators (B2B), Public Healthcare System (SUS - B2B)
4 Limited Access to Specialized/High-Complexity Tests Patients (B2C), Public Healthcare System (SUS - B2B)
5 Lack of Seamless Data Integration Patients (B2C), Physicians (B2B interface), Hospitals/Clinics (B2B)
6 Shortage of Skilled Professionals (for interpretation/services) Physicians (B2B interface), Diagnostic Service Providers (Internal)
7 Bureaucratic Claims & Authorization Processes Health Insurance Operators (B2B), Diagnostic Service Providers (Internal)
8 High Cost/Difficulty in Procuring Equipment/Reagents Hospitals/Clinics (B2B), Other Laboratories (B2B)
9 Regulatory Hurdles & Compliance Burden Manufacturers (Internal), Distributors (Internal), Service Providers (Internal)

Note: Challenges marked as "Internal" primarily affect players within the value chain (providers, manufacturers, distributors) but directly translate into pains for the final customers (e.g., affecting cost, availability, quality).

Correlation with Value Chain

The challenges and pains faced by customers are directly correlated with bottlenecks and inefficiencies at specific steps within the Diagnostic Medicine value chain in Brazil:

  • Access Disparities & Long Waiting Times (Priority 1): This pain point for patients, particularly within the SUS, is a direct consequence of issues in the Healthcare Service Delivery and Utilization step, reflecting the fragmentation of the health system and limitations in the capacity and distribution of Diagnostic Service Provision facilities, especially in the public sector and less developed regions.
  • Pressure on Reimbursement Rates & Payment Delays (Priority 2): This is a core challenge within the Financing and Reimbursement step, highlighting the often-contentious commercial relationships and business models between health insurance operators (payers) and Diagnostic Service Provision entities. These financial pressures on providers can indirectly impact patients through potential limitations in service offerings or investment in technology.
  • Cost of Services & Affordability (Priority 3): The cost borne by customers (patients directly, or payers on behalf of populations) is influenced by costs accumulated throughout the value chain. This includes the cost of imported products and logistics in Research, Development, and Manufacturing and Distribution and Commercialization, as well as operational costs and technology investment in Diagnostic Service Provision. The models in Financing and Reimbursement determine how these costs are passed on or managed.
  • Limited Access to Specialized/High-Complexity Tests (Priority 4): This issue for patients, especially in the public system or remote areas, relates to the capabilities and reach of Diagnostic Service Provision and the ability of Financing and Reimbursement mechanisms (particularly the low SUS table) to support the provision of more expensive or complex procedures.
  • Lack of Seamless Data Integration (Priority 5): This challenge is linked to the Software and IT Solutions Development segment within Research, Development, and Manufacturing, and its implementation and interoperability within Diagnostic Service Provision and Healthcare Service Delivery and Utilization.
  • Shortage of Skilled Professionals (Priority 6): This operational pain point for service providers and physicians is primarily situated within the Diagnostic Service Provision step and is related to the availability and training of personnel, potentially linking back to educational institutions and Professional Regulation.
  • Bureaucratic Claims & Authorization Processes (Priority 7): This administrative burden is a direct interaction challenge within the Financing and Reimbursement step between health insurance operators and Diagnostic Service Provision entities.
  • High Cost/Difficulty in Procuring Equipment/Reagents (Priority 8): This pain for hospitals and other labs directly relates to the cost structure and efficiency of the Research, Development, and Manufacturing (especially import dependency) and Distribution and Commercialization steps of the value chain.
  • Regulatory Hurdles & Compliance Burden (Priority 9): While primarily impacting players within the chain (manufacturers, distributors, providers), the complexity and delays in Regulation and Oversight can indirectly affect customers by delaying the availability of new technologies or adding to the cost of services.

In conclusion, the challenges and pains experienced by the final customers in Brazil's diagnostic medicine sector are deeply intertwined with the operational, financial, and regulatory bottlenecks present throughout the value chain, from the sourcing of materials to the final delivery and reimbursement of services.

References

  • Afip: Afip lança unidade de negócios de medicina diagnóstica. https://www.afip.com.br/afip-lanca-unidade-de-negocios-de-medicina-diagnostica/
  • Associação Brasileira de Medicina Diagnóstica (Abramed): Pesquisa revela que brasileiros realizaram 2,4 bilhões de exames de diagnóstico em 2023. https://abramed.org.br/pesquisa-revela-que-brasileiros-realizaram-24-bilhoes-de-exames-de-diagnostico-em-2023/
  • Conrad: Perspectivas da medicina diagnóstica para 2025. https://conradweb.com.br/perspectivas-da-medicina-diagnostica-para-2025/
  • Estadão: Fusões e aquisições no setor de saúde disparam no 1º trimestre, diz PwC. https://www.estadao.com.br/economia/fusoes-e-aquisicoes-no-setor-de-saude-disparam-no-1-trimestre-diz-pwc/
  • FGV EAESP: Impacto Da Criação Da Associação Brasileira De Medicina Diagnóstica (Abramed) Como Estratégia De Competitividade No Setor Privado De Serviços Diagnósticos No Brasil. https://bibliotecadigital.fgv.br/dspace/handle/10438/18544
  • Futuro da Saúde: Medicina diagnóstica: o que esperar do setor nos próximos anos. https://futurodasude.com.br/medicina-diagnostica-o-que-esperar-do-setor/
  • Hospital São Paulo: Saúde Suplementar. https://hospitalsaopaulo.org.br/saude-suplementar
  • Interfarma: Medicina diagnóstica tem papel decisivo na saúde suplementar. https://interfarma.org.br/noticias/medicina-diagnostica-tem-papel-decisivo-na-saude-suplementar
  • Medicina SA: Mercado de dispositivos médicos e diagnóstico in-vitro cresceu 57,9%. https://medicinasa.com.br/mercado-dispositivos-medicos/
  • Mobilemed: Tendências e desafios da Medicina Diagnóstica. https://mobilemed.com.br/tendencias-e-desafios-da-medicina-diagnostica/
  • Mordor Intelligence: Tamanho do mercado de diagnóstico in vitro do Brasil e análise de ações – Tendências e previsões de crescimento (2024 - 2029). https://www.mordorintelligence.com/pt/industry-reports/brazil-in-vitro-diagnostics-market
  • Percepção de Valor em Serviços de Medicina Diagnóstica. https://www.saudebusiness.com/gestao/percepcao-de-valor-em-servicos-de-medicina-diagnostica
  • Revistas PUC-SP: O segmento da medicina diagnóstica no Brasil. https://revistas.pucsp.br/RFCMS/article/download/26500/18754/62758
  • Saúde Business: Medicina diagnóstica: perspectivas otimistas para o próximo ano. https://www.saudebusiness.com/gestao/medicina-diagnostica-perspectivas-otimistas-para-o-proximo-ano
  • Saúde Business: Fusões e aquisições no setor de saúde ganham impulso em 2024. https://www.saudebusiness.com/fusoes-e-aquisicoes/fusoes-e-aquisicoes-no-setor-de-saude-ganham-impulso-em-2024
  • Shift: Tendências na medicina diagnóstica para 2025: inovação, eficiência e foco no paciente. https://medical.shift.com.br/tendencias-medicina-diagnostica-2025/
  • Shopplab Notícias: O Mercado Brasileiro de Medicina Diagnóstica: um Panorama Atual. https://www.shopplab.com.br/blog/o-mercado-brasileiro-de-medicina-diagnostica-um-panorama-atual/
  • Terra: Com crescimento de 25%, fusões e aquisições no setor de saúde quebram recorde. https://www.terra.com.br/economia/com-crescimento-de-25-fusoes-e-aquisicoes-no-setor-de-saude-quebram-recorde,72a1619778a872bb3f2529c7d709520by1u7137k.html
  • Terra: Fusões e aquisições no setor de saúde devem crescer este ano, com foco regional, diz consultoria. https://www.terra.com.br/economia/fusao-e-aquisicao/fusoes-e-aquisicoes-no-setor-de-saude-devem-crescer-este-ano-com-foco-regional-diz-consultoria,5156b31a6f66c4244878f249604280cahc8432oq.html